Carbonyl reductase as well as mutant gene and application thereof
A carbonyl reductase from Rhodosporidium toruloides, optimized in E. coli BL21, addresses the inefficiencies of existing tolvaptan synthesis methods by achieving high enantiomeric excess and yield of optically pure tolvaptan with improved yields and environmental friendliness.
Patent Information
- Application Number
- CN202411398072.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-09
- Publication Date
- 2024-12-06
AI Technical Summary
Existing methods for producing optically active tolvaptan, such as chemical synthesis and lipase-catalyzed transesterification, are costly, environmentally unfriendly, and have unsatisfactory yields, limiting large-scale applications.
A carbonyl reductase derived from Rhodosporidium toruloides, combined with a glucose dehydrogenase, is expressed in Escherichia coli BL21 (DE3) using a pET-30a plasmid, and optimized through mutagenesis to enhance enantioselectivity and efficiency for the biosynthesis of (S)-tolvaptan.
The system achieves high enantiomeric excess and yield of optically pure tolvaptan with mild reaction conditions, providing a cost-effective and environmentally friendly biocatalytic process.
Smart Images

Figure CN119082149A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of enzyme engineering, and in particular to a carbonyl reductase and a mutant gene and application thereof. Background Art
[0002] Tolvaptan is the first and only oral competitive vasopressin V2 receptor antagonist and has been approved by the U.S. Food and Drug Administration for the treatment of clinically significant severe hyponatremia and isovolumetric hyponatremia. Tolvaptan is currently marketed in the form of a racemate. However, researchers have found that in mammals, injectable formulations containing optically active tolvaptan (S-(-)-tolvaptan or R-(+)-tolvaptan) have higher metabolic stability than racemic tolvaptan for the prevention or treatment of polycystic kidney disease. It has also been found that intramuscular administration of an aqueous suspension of optically active tolvaptan produces higher serum concentrations than the racemic compound. In addition, the absorption rate of optically active tolvaptan in vitro is higher than that of racemic tolvaptan. In order to elucidate the mechanism of action and pharmacological characteristics of enantiopure tolvaptan, the asymmetric preparation of optically active isomers becomes particularly important.
[0003] The traditional method for preparing optically active tolvaptan is chemical synthesis. Such methods all require the use of chiral reagents for asymmetric catalytic reactions, which have some disadvantages. The synthesis of chiral reagents is complicated and expensive, and the compounds themselves are toxic, which leads to high costs for industrial applications and is associated with environmental issues. Compared with chemical synthesis, biosynthesis provides an alternative method for preparing enantiopure tolvaptan. Matsubar reported a method for the enantioselective synthesis of tolvaptan metabolites by lipase-catalyzed transesterification. Although this method can prepare both enantiomers of the target compound with high enantiomeric excess (99% ee), the asymmetric reaction system usually has unsatisfactory yields (70%), which poses a bottleneck for large-scale application. Therefore, from the perspective of environment and practice, it is necessary to develop a more efficient biosynthetic method to produce enantiopure tolvaptan. Summary of the invention
[0004] The purpose of the present invention is to provide a carbonyl reductase with enantioselectivity, mild reaction conditions and environmental friendliness, and a mutant gene and application thereof.
[0005] The present invention adopts the following technical solution: A carbonyl reductase gene derived from Rhodosporidium toruloides ( Rhodosporidium toruloides ), the nucleotide sequence is shown in SEQ ID No.4.
[0006] A carbonyl reductase encoded by the carbonyl reductase gene, whose amino acid sequence is shown in SEQ ID No.3.
[0007] A fusion protein gene encoding the co-expression of the carbonyl reductase and glucose dehydrogenase, the nucleotide sequence of which is shown in SEQ ID No.6.
[0008] An expression vector comprising the carbonyl reductase gene or the fusion protein gene.
[0009] Furthermore, the expression vector is pET-30a plasmid.
[0010] An engineered bacterium comprises the above expression vector.
[0011] Furthermore, the engineered bacteria is Escherichia coli BL21 (DE3).
[0012] An application of the carbonyl reductase gene in catalyzing the synthesis of (S)-tolvaptan.
[0013] A carbonyl reductase mutant gene, wherein the G at position 224 of the carbonyl reductase gene is mutated to C, the C at position 526 is mutated to T, and the C at position 511 is mutated to G, and the nucleotide sequence thereof is shown in SEQ ID No.8.
[0014] A carbonyl reductase mutant encoded by the carbonyl reductase mutant gene has an amino acid sequence as shown in SEQ ID No.7.
[0015] A mutant fusion protein gene co-expressed by the carbonyl reductase mutant and glucose dehydrogenase, the nucleotide sequence of which is shown in SEQ ID No.11.
[0016] A mutant expression vector comprises a carbonyl reductase mutant gene or a mutant fusion protein gene.
[0017] Furthermore, the expression vector is pET-30a plasmid.
[0018] An engineered bacterium comprises the mutant expression vector.
[0019] Furthermore, the engineered bacteria is Escherichia coli BL21 (DE3).
[0020] An application of the carbonyl reductase mutant gene in catalyzing the synthesis of (S)-tolvaptan.
[0021] The beneficial effects of the present invention are as follows: the carbonyl reductase and its mutants of the present invention have outstanding enantioselectivity, mild reaction conditions and environmental friendliness, and are valuable biocatalysts for reducing prochiral ketones to chiral alcohols. In addition, the present invention provides an efficient method for asymmetric reduction by co-expressing carbonyl reductase and glucose dehydrogenation in a recombinant whole cell system for regeneration of cofactor NADPH or NADH. Therefore, the present invention is of great significance for exploring carbonyl reductases that can catalyze the synthesis of optically pure tolvaptan. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Agarose gel electrophoresis of PCR products; Wherein, M: DNA marker; lane1: RT .
[0023] Figure 2 This is the SDS-PAGE detection image after Ni column purification; Among them, M: protein marker; lane1: recombinant protein induced by adding IPTG E. coli BL21 (DE3) / pET-30a- RT lane2: the supernatant of the broken protein; lane2: the target protein RhtCR after purification.
[0024] Figure 3 The relative enzyme activity analysis results of RhtCR on PK catalysis at different temperatures and pH.
[0025] Figure 4 This is the SDS-PAGE image of the bifunctional protein; Wherein, M: molecular weight marker; lane 1: recombinant strain without IPTG induction; lane 2: recombinant strain with IPTG induction.
[0026] Figure 5 The effect of substrate concentration on PK conversion rate.
[0027] Figure 6 The effect of conversion time on PK conversion rate.
[0028] Figure 7 The results of HPLC analysis of PK, (S)-tolvaptan and (R)-tolvaptan using chiral columns; Among them, a: a mixture of racemic tolvaptan standard and PK standard; b: liquid chromatogram of PK after whole-cell transformation. DETAILED DESCRIPTION
[0029] The present invention is described in detail below with reference to specific embodiments and accompanying drawings.
[0030] Example 1 Cloning, expression and purification of carbonyl reductase The genomic DNA of Rhodosporidium toruloides preserved in the laboratory was extracted and purified using the Total Gold Genomic DNA Extraction Kit. Primers for amplification of the gene were designed using Primer Premier 5.5 based on the putative carbonyl reductase sequence in other Rhodosporidium toruloides genomes registered in the NCBI database (BioProject: PRJEB6139).
[0031] CRf (SEQ ID No. 1):cagtGAATTCATGGTCAAGCTCCCGACC; CRr (SEQ ID No. 2):cagtAAGCTTTTTAGAACTCCATCGCACCCT.
[0032] PCR amplified the DNA fragment of the carbonyl reductase gene. From the electrophoresis results, it can be clearly seen that PCR amplification obtained a single nucleic acid band with a size of about 1500 bp (such as Figure 1 As shown), it can be used for the construction of recombinant plasmid and recombinant bacteria in the next step.
[0033] The amplified fragment was inserted into the expression vector pET-30a. Eco RI and Hin The obtained plasmid was transformed into Escherichia coli BL21 (DE3). The activity of the prochiral ketone 7-chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzeneazepine (PK) was tested using whole cells of recombinant E. coli to select an effective carbonyl reductase. Then, the purified amplification product and plasmid were verified by DNA sequencing. Finally, the gene encoding the carbonyl reductase was obtained. RT The amino acid sequence encoding carbonyl reductase is shown in SEQ ID No. 3. RT The nucleotide sequence of the gene is shown in SEQ ID No.4.
[0034] Recombinant Escherichia coli BL21 (DE3) / pET-30a- RTCultured at 28 °C in LB medium containing 0.5 mM kanamycin. When the optical density of the culture at 600 nm reached 0.8, IPTG was added to a final concentration of 0.1 mM and culture was continued at 30 °C for 14 h. Cells were harvested by centrifugation (8000 × g, 10 min) at 4 °C, washed twice with 20 mM Tris-HCl buffer (pH 7.5), and lysed by sonication using an ultrasonic oscillator (Sonic Materials, Newton, CT, USA). Cell debris was removed by centrifugation (9000 × g, 15 min) at 4 °C, and the supernatant was filtered through a 0.45 μm filter and applied to an affinity column (HisTrap HP; GE Healthcare, Piscataway, NJ, USA) equilibrated with 20 mM Tris-HCl (pH 7.5) and 0.5 M NaCl. The samples were eluted in 20 mM Tris-HCl (pH 7.5), 0.5 M NaCl, and 0.5 M imidazole using a purification system (ÉKTA pure; GE Healthcare). The purified enzyme solution was subsequently desalted and concentrated by ultrafiltration using an ultrafiltration membrane (Ultracel-10; Millipore, Billerica, MA, USA). The purified enzyme was evaluated by Coomassie brilliant blue staining of SDS-polyacrylamide gel electrophoresis (PAGE) gels.
[0035] from Figure 2 The recombinant strain can be clearly seen in E. coli BL21 (DE3) / pET-30a- RT Under the induction of IPTG, carbonyl reductase RhtCR can be overexpressed, indicating that the recombinant strain is successfully constructed. A relatively pure carbonyl reductase RhtCR can be obtained through the protein purification process for subsequent enzyme activity determination.
[0036] Example 2 Enzyme activity determination To detect the enzymatic activity of carbonyl reductase RhtCR, as well as the optimal catalytic temperature and pH, an enzymatic activity assay of RhtCR was performed. The activity of RhtCR was determined by measuring the change in NADH absorbance at 340 nm for 1 min on a multi-detection microplate reader (Synergy HT; BioTek, Winooski, VT, USA). The reaction mixture (0.1 mL) for the enzyme assay included 20 mM Tris-HCl buffer (pH 7.5), 1.0 mM NADH (NADPH), 8 mM prochiral ketone, and the appropriate enzyme. One unit (U) of enzyme activity was defined as the amount of enzyme that catalyzes the formation and oxidation of 1 μmol NADH (NADPH) / min. Each experiment was performed in triplicate.
[0037] The enzyme catalytic conditions were optimized as follows: The optimal pH of RhtCR was determined at pH 4.0–9.0 using 100 mM NaAC HAC (pH 4.0–6.0), 100 mM potassium phosphate (pH 6.0–7.0), or 100 mM Tris-HCl buffer (pH 7.0–9.0). The optimal temperature was estimated by testing at 20–70 °C under standard conditions. The relative activity of RhtCR at each optimal pH and temperature for the reduction reaction was defined as 100%.
[0038] From the above enzyme activity test results, we can know that ( Figure 3 ), RhtCR showed reducing activity in the presence of NADPH, but almost no activity in the presence of NADH, indicating that the enzyme is a single coenzyme-specific carbonyl reductase. The enzyme used prochiral ketone PK as a substrate, and the specific activity of the reductase was 40.3 U / mg, which is much higher than the enzyme activity of alcohol dehydrogenase used to catalyze PK reported in existing literature. The purified RhtCR showed the best enzyme activity at a temperature of 50°C and a pH of 5.0, indicating that the enzyme has certain high temperature and acid resistance characteristics, which is beneficial to the downstream application of the enzyme.
[0039] Example 3 Construction of the co-expression system of carbonyl reductase RhtCR and GDH in Escherichia coli Because the carbonyl reductase is a coenzyme-dependent enzyme, in order to create a coenzyme regeneration system, the glucose dehydrogenase (GDH) screened in the early stage and the carbonyl reductase were used to construct a co-expression system. The operation process is as follows: the RhtCR and GDH functional enzyme genes are connected by Linker (SEQ ID No.5: GAAGGATATACC), and the gene of the cloned fusion protein RhtCR-Linker-GDH (SEQ ID No.6) is cloned into the pET-30a plasmid using the improved overlap extension technology. The recombinant plasmid pET-30a- rhrcr&gdh Transformed into competent E. coli BL21 (DE3) and verified by DNA assay. rhrcr&gdh The clone was successful. The strain was induced by IPTG, the collected bacteria were ultrasonically disrupted, and the supernatant of the disrupted liquid was analyzed by SDS-PAGE to analyze the co-expression of RhtCR and GDH proteins in the recombinant strain.
[0040] Depend on Figure 4 It can be seen that the recombinant strain pET-30a- rhrcr&gdh RhtCR (56 kDa) and GDH (45 kDa) can be expressed under the induction of IPTG, indicating that the co-expression system of the two functional proteins was successfully constructed.
[0041] Example 4 Optimization of the whole-cell catalytic system of the recombinant strain The prochiral ketone PK was recombined into the recombinant strain pET-30a- rhrcr&gdh The effect of different substrate concentrations on the catalytic efficiency was first tested. rhrcr&gdh 2 g of wet bacteria was added to 4 100 mL conical bottles with stoppers, and then 20 mg, 40 mg, 60 mg, and 80 mg of PK were added respectively, and 2 mL of soybean oil was added. Finally, each bottle was fixed to 20 mL with 0.1M, pH = 7.2 potassium phosphate buffer and the stopper was covered. The reaction system was placed in a constant temperature shaker at 30°C and 150 rpm for incubation, and the concentrations of prochiral ketone and tolvaptan were analyzed by HPLC to investigate the effect of substrate concentration on conversion rate.
[0042] After the substrate concentration was determined, the effect of different conversion times on the catalytic efficiency was tested. The above culture process was repeated, and samples were taken at different conversion times (every 6 h). 50 μL of the oil layer was taken, 500 μL of acetonitrile was added, and the mixture was thoroughly shaken and mixed, and then centrifuged at 10,000 g for 2 min. The acetonitrile layer was filtered through a 0.22 μm pore size nylon 66 material filter membrane and then analyzed by HPLC to examine the effect of different times on the conversion rate.
[0043] Then, the reaction mixture was extracted with an equal volume of ethyl acetate. The solvent was removed by rotary evaporation at 50°C. The dried metabolites were redissolved in methanol and the target product was purified on preparative HPLC. The collected product solution was evaporated to obtain the final product dry powder.
[0044] HPLC conditions are as follows: Agilent Extend C-18 (4.6 mm × 250 mm, 5 μm) was used to analyze the concentrations of the product and substrate in the sample, and a chiral column CHIRALOAKID (4.6 mm × 250 mm, 5 μm) was used to analyze the concentrations of (R) configuration and (S) configuration in the sample. Mobile phase conditions: A is 0.05% trifluoroacetic acid in water, B is 0.05% trifluoroacetic acid in acetonitrile, UV detection wavelength is 254 nm, injection volume is 5 μL, flow rate is 1 mL / min, column temperature is 30°C, mobile phase A: mobile phase B = 45%: 55%, isocratic elution. Conversion rate (%) and enantiomeric excess value ( ee ) is calculated as follows: Conversion rate (%) = C 底物 / C 产物 ; ee = (C R产物 -C S产物 ) / (C R产物 +C S产物 )×100%.
[0045] In the formula, C 底物 represents the initial concentration of PK, C 产物 represents the concentration of tolvaptan at the end of the reaction, C R产物 , C S产物 Represents the concentrations of (R) and (S) tolvaptan, respectively.
[0046] Results and Discussion: (1) Effect of substrate concentration on conversion The substrate concentration not only affects the dissolution of the substrate in soybean oil, but also affects the contact efficiency between the substrate and the bacteria, and ultimately affects the amount of product generated. Therefore, the effect of different substrate concentrations on the conversion rate of the catalytic reaction was investigated.
[0047] from Figure 5 It can be seen that the conversion rate of the bacteria is the highest at a substrate concentration of 10 mg / mL, which is 88.4%. When the concentration is 20 mg / mL, the conversion rate is reduced to 81.2%. As the substrate concentration continues to increase, the conversion rate decreases. When the substrate concentration is 30 mg / mL, the conversion rate drops to 39.3%, and when the substrate concentration is 40 mg / mL, the conversion rate is only 28.5%. Considering the substrate concentration, conversion rate and cost saving, 10 mg / mL is selected as the optimal addition concentration of the substrate.
[0048] (2) Effect of transformation time on whole-cell transformation rate The investigation of the conversion time in the catalytic system can well control the progress of the catalytic reaction. The following is an investigation of the relationship between the reaction time and catalytic capacity of the two-phase conversion system. The results are as follows Figure 6 .
[0049] In the whole-cell conversion of tolvaptan intermediates, the conversion rate increased steadily with time, and the conversion rate increase and time increase were almost linear. After the whole-cell culture time accumulated to 72 h, the conversion rate reached a maximum of 87.8%; the conversion rate did not increase during 72 h to 80 h, and the conversion system reached a plateau; until 80 h of culture, the conversion rate gradually decreased and the product was consumed. Therefore, we chose 72 h as the optimal conversion time under the catalytic system.
[0050] Example 5 Optical properties of conversion products After the optimization of the catalytic conversion system was completed, the configuration of the product tolvaptan was analyzed. The (R) and (S) configuration tolvaptan standards and the products of whole cell conversion were analyzed by HPLC using a chiral column. Figure 7 As shown, the retention times of (R)-tolvaptan standard and (S)-tolvaptan standard in the chromatogram are 10.31 min and 4.92 min, respectively.
[0051] Recombinant strain pET-30a- rhrcr&gdh Comparison of the retention time of the whole cell conversion product and the standard revealed that the conversion product was tolvaptan in the (S) configuration. Peak area calculation showed that the proportions of different chiral structures in the conversion product were as follows: the mass fraction of tolvaptan in the (R) configuration was 0.5%, the mass fraction of tolvaptan in the (S) configuration was 99.5%, and the mass fraction of the product was ee The value was 99%. The results reflect that the recombinant strain pET-30a- rhrcr&gdh The catalysis of tolvaptan intermediates has very good chiral selectivity, and the (S) configuration is the main product.
[0052] Example 6 Random mutagenesis screening of carbonyl reductase mutants Using the pET-30a- RT Plasmid as template, error-prone PCR amplification with primers RT gene, and the upstream and downstream primers were added Eco RI and Hin dIII restriction endonuclease cleavage site. Error-prone PCR reaction was performed according to the instructions of the Gene Random Mutation Kit of Bio-Tech. The PCR amplification product was subjected to 1% agarose gel electrophoresis, and the gel was cut and purified to recover the target band. RT Both the gene fragment and the pET-30a vector were Eco RI and Hin After 3 h of double digestion with dIII, the recovered products were mixed at a ratio of 3:1, and T4 DNA ligase was added overnight to transform Escherichia coli BL21 (DE3) competent cells, and spread on solid LB plates (100 μg / mL Kan). Positive transformants were selected for resistance. All transformants consisted of RT Gene mutant library.
[0053] The positive transformants were selected and inoculated into 96-well deep-well plates containing LB medium. After culturing for 24 h, the bacterial precipitates were collected by centrifugation. The two-phase catalytic system of soybean oil / buffer was also used to evaluate the PK (final concentration of 10 mg / mL) of whole-cell catalysis of prochiral ketones. After 72 h of transformation, 50 μL of the oil layer was taken, 500 μL of acetonitrile was added, and the mixture was thoroughly shaken and mixed, and then centrifuged at 10000 g for 2 min. The acetonitrile layer was filtered through a 0.22 μm pore size nylon 66 material filter membrane and then analyzed by HPLC to examine the transformation ability of the transformants.
[0054] According to the above random mutation library construction and screening method, three rounds of error-prone mutations were carried out on the carbonyl reductase, and a total of about 10 4The initial screening of mutants resulted in 42 mutants with improved activity ratios. These 42 mutants were then rescreened to quantitatively compare the catalytic efficiency and soluble expression of these mutants and the wild-type carbonyl reductase. Finally, two mutants with improved catalytic efficiency and soluble expression were identified, named mutant DsRhtCR. 1 and DsRhtCR 2 The two mutants were serially passaged, and the plasmid genetic stability was good, and the soluble expression of the protein did not change.
[0055] The two strains were sent for sequencing to determine the mutation site of the gene. 1 The amino acid sequence of the carbonyl reductase mutant is shown in SEQ ID No.7, corresponding to RT The base sequence of the mutant gene is shown in SEQ ID No. 8. DsRhtCR 2 The amino acid sequence of the carbonyl reductase mutant is shown in SEQ ID No.9, corresponding to RT The base sequence of the mutant gene is shown in SEQ ID No.10.
[0056] Table 1 Comparison of catalytic activity of carbonyl reductase before and after mutation .
[0057] Sequence analysis of the mutant genes showed that three bases of the mutant genes had mutated, DsRhtCR 1 and DsRhtCR 2 The bases of the mutants are shown in Table 1. 1 The mutation sites of the mutant are G to C at position 224, C to T at position 526, and C to G at position 511. 2 The mutation sites of the mutant are A to T at position 711, T to C at position 1060, and C to G at position 1360.
[0058] The newly constructed mutant gene-engineered bacteria E. coli BL21 / pET-30a- rhtcr1 and E. coli BL21 / pET- 30a-rhtcr2 Compared with the previous engineered strains E. coli BL21 / pET-30a- RT The expression was induced separately, and the bacteria were collected for enzyme catalysis reaction. It was found that the optimal temperature and pH of the strain catalysis were not much different from those of the original enzyme.
[0059] The two carbonyl reductase mutant genes were replaced by the original pET-30a- rhrcr&gdhOn the plasmid rhrcr Gene, two new co-expression plasmids were successfully constructed, namely pET-30a- rhrcr1&gdh and pET-30a- rhrcr2& gd Among them, the fusion protein DsRhtCR 1 -Linker-GDH gene is shown in SEQ ID No.11, fusion protein DsRhtCR 2 The gene of -Linker-GDH is shown in SEQ ID No. 12. The plasmid was successfully transformed into E. coli BL21 (DE3) cells to form two new co-expression strains named E. coli BL21 / pET-30a- rhrcr1&gdh and E. coli BL21 / pET-30a- rhrcr2&gdh. The two new transformed strains were induced to express and the bacterial cells were collected to verify the substrate conversion. When the substrate concentration was increased to 30 g / L, the strain was found to E. coli BL21 / pET-30a- rhrcr2&gdh DsRhtCR 2 The substrate tolerance of the strain was good, and the conversion effect of the high-concentration substrate was good, which was better than that of the original strain ( E. coli BL21 / pET-30a- rhrcr&gdh ) The conversion rate increased by about 2 times, indicating that the mutation site of the strain may be directly related to the enhancement of substrate tolerance.
[0060] Example 7 Substrate spectrum of carbonyl reductase mutants Using a mutant DsRhtCR containing carbonyl reductase 2 Strains E. coli BL21 / pET-30a- rhrcr2&gdh Catalytic studies were conducted on different α-aryl ketone compounds, with the substrate concentration being 30 g / L. The results are shown in the following table: Table 2 Containing DsRhtCR 2 Substrate spectrum of mutant strains .
[0061] The strain has high catalytic activity for other aromatic ketone compounds, indicating that the engineered bacteria containing carbonyl reductase mutants have broad application prospects and can be used in the synthesis and production of other chiral drug intermediates. In particular, the catalytic efficiency of 2-chloro-1-(3,4-difluorophenyl)ethanone can reach 100%, and its synthetic product is (1S)-2-chloro-1-(3,4-difluorophenyl)ethanol, which is a key drug intermediate for the synthesis of small molecule anticoagulant ticagrelor. In the future, further research and exploration of the strain's synthesis of other chiral compounds can be carried out.
Claims
1. A carbonyl reductase gene, characterized in that: Its nucleotide sequence is shown in SEQ ID No.
4.
2. A carbonyl reductase encoded by the carbonyl reductase gene according to claim 1, characterized in that: Its amino acid sequence is shown in SEQ ID No.
3.
3. A fusion protein gene encoding the co-expressed carbonyl reductase and glucose dehydrogenase according to claim 2, characterized in that: Its nucleotide sequence is shown in SEQ ID No.
6.
4. A carbonyl reductase mutant gene, characterized in that: In the carbonyl reductase gene of claim 1, G at position 224 is mutated to C, C at position 526 is mutated to T, and C at position 511 is mutated to G.
5. A carbonyl reductase mutant encoded by the carbonyl reductase mutant gene according to claim 4, characterized in that: Its amino acid sequence is shown in SEQ ID No.
7.
6. A mutant fusion protein gene encoding the carbonyl reductase mutant and glucose dehydrogenase co-expressed according to claim 5, characterized in that: Its nucleotide sequence is shown in SEQ ID No.
11.
7. An expression vector, characterized in that: It comprises one of the following genes: the carbonyl reductase gene according to claim 1, the fusion protein gene according to claim 3, the carbonyl reductase mutant gene according to claim 4, and the mutant fusion protein gene according to claim 6.
8. An engineered bacterium, characterized in that: Comprising the expression vector as described in claim 7.
9. Use of the carbonyl reductase gene as claimed in claim 1 in catalytic synthesis of (S)-tolvaptan.
10. Use of the carbonyl reductase mutant gene as claimed in claim 4 in catalytic synthesis of (S)-tolvaptan.
